RCMU
VRTX icon

Rokos Capital Management (UK)’s Vertex Pharmaceuticals VRTX Stock Holding History

Rokos Capital Management (UK)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-258,664
Closed -$51.3M – 157
2021
Q2 		$51.3M Buy
+258,664
New +$54.1M 1.02% 26

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rokos Capital Management (UK)'s VRTX Position: Q3 2021 in Review

Rokos Capital Management (UK) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 258,664 shares — an estimated $51.3M sold.

Rokos Capital Management (UK) first reported a position in VRTX in Q2 2021 and held it in 1 quarter. The position peaked at $51.3M in Q2 2021. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Rokos Capital Management (UK) reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Rokos Capital Management (UK) sold 258,664 Vertex Pharmaceuticals shares in Q3 2021, an estimated $51.3M.
  • Rokos Capital Management (UK) first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Rokos Capital Management (UK)'s Vertex Pharmaceuticals position peaked at $51.3M in Q2 2021.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Rokos Capital Management (UK)'s 13F filing for Q3 2021, filed 15 Nov 2021.